# Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer

> **NCT00687817** · PHASE2 · COMPLETED · sponsor: **Peregrine Pharmaceuticals** · enrollment: 49 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** bavituximab plus paclitaxel and carboplatin

## Key facts

- **NCT ID:** NCT00687817
- **Lead sponsor:** Peregrine Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2011-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00687817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00687817, "Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00687817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*